{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:29:53Z","timestamp":1793456993388,"version":"4.5.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Measles, Mumps, and Rubella (MMR) vaccine is a cornerstone of global pediatric health, yet its uptake has been declining amid growing public sensitivity about vaccine safety. This study aimed to analyze the occurrence of adverse events following immunization (AEFI) following MMR administration in Zhejiang Province from January 1, 2020, to December 31, 2025, to evaluate the vaccine's post-marketing safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AEFI cases reported following MMR vaccination in Zhejiang Province between 2020 and 2025 were collected via the Chinese National Adverse Events Following Immunization Information System (CNAEFIS). Descriptive epidemiological methods were employed to analyze and evaluate the reported data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2020 to 2025, a total of 12,597 MMR-related AEFI cases were reported, yielding an overall incidence rate of 213.15 per 100,000 doses. Among these, common adverse reactions, rare adverse reactions, and coincidental events accounted for 10,113 cases (171.12\/100,000), 2,421 cases (40.96\/100,000), and 63 cases (1.07\/100,000), respectively. Incidence rates varied significantly by region (range: 177.30\u2013260.45\/100,000). The male-to-female ratio was 1.16:1, with 76.49% of cases occurring in children \u22641 year of age. Reports peaked during the summer and were primarily associated with the first dose. Clinical manifestations were dominated by common reactions such as fever (70.75%), rash (42.81%), and irritability (20.38%). The co-administration group exhibited significantly higher rates of high fever and rash than the MMR-only group. A total of 68 severe AEFIs were reported, with an incidence rate of 1.15 per 100,000 doses. Notably, 95.49% of cases improved without clinical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MMR demonstrates a safe profile in Zhejiang Province. Future efforts should focus on peak reaction periods, enhancing public communication, and strengthening primary care physician training to maintain high surveillance sensitivity and improve diagnostic and emergency response capabilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1846354","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:56:22Z","timestamp":1781675782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020\u20132025"],"prefix":"10.3389","volume":"14","author":[{"given":"Xuejiao","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102698","DOI":"10.1016\/j.omtn.2025.102698","article-title":"Measles and rubella: from global health challenges to advancements in molecular diagnostics in the elimination era","volume":"36","author":"Sharma","year":"2025","journal-title":"Mol Ther Nucleic Acids."},{"key":"B2","unstructured":"Geneva\n          World Health Organization.\n          Measles\n          \n          2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/cimb48020206","article-title":"Measles: an updated literature review of the host response, pathogenesis, complications, prevention measures, and recent outbreaks","volume":"13","author":"Au","year":"2026","journal-title":"Curr Issues Mol Biol Feb."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20210153","DOI":"10.1098\/rsif.2021.0153","article-title":"Immune amnesia induced by measles and its effects on concurrent epidemics","volume":"18","author":"Morales","year":"2021","journal-title":"J R Soc Interface Jun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1080\/21645515.2021.2007710","article-title":"Prevention of measles, mumps and rubella: 40 years of global experience with M-M-R(II)","volume":"17","author":"Kuter","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.pedn.2025.11.008","article-title":"Misinformaion and its impact on measles vaccine hesitancy in the pediatric population: a scoping review","volume":"86","author":"Anson","year":"2026","journal-title":"J Pediatr Nurs Jan-Feb."},{"key":"B7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12985-025-03022-z","article-title":"Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD((R))) reported to the vaccine adverse event reporting system (VAERS), 2015-2025","volume":"22","author":"Liang","year":"2025","journal-title":"Virol J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.15585\/mmwr.mm7345a4","article-title":"Progress toward measles elimination - worldwide, 2000-2023","volume":"73","author":"Minta AA","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jama.2024.25514","article-title":"Global measles cases rose 20% in 1 year as vaccine coverage fell short","volume":"333","author":"Anderer","year":"2025","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101347","DOI":"10.1016\/j.lanmic.2026.101347","article-title":"Global resurgence in measles","volume":"29","author":"Venkatesan","year":"2026","journal-title":"Lancet Microbe"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2624148","DOI":"10.1080\/17441692.2026.2624148","article-title":"Resurgence of measles in the United States: examining the outbreak, vaccine hesitancy, and future directions","volume":"21","author":"Edward","year":"2026","journal-title":"Glob Public Health."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E224","DOI":"10.1503\/cmaj.251433","article-title":"Immunization registries: an essential tool for measles elimination in Canada","volume":"198","author":"Brown","year":"2026","journal-title":"CMAJ."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e88196","DOI":"10.7759\/cureus.88196","article-title":"The 2025 United States measles crisis: when vaccine hesitancy meets reality","volume":"17","author":"Adeoye","year":"2025","journal-title":"Cureus Jul."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines9020143","article-title":"Humoral immunity against measles in mother-infant pairs during the first year of life in greece: a cross-sectional study","volume":"10","author":"Kanakoudi-Tsakalidou","year":"2021","journal-title":"Vaccines."},{"key":"B15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40124-022-00278-9","article-title":"Vaccine hesitancy: obstacles and challenges","volume":"10","author":"Galagali","year":"2022","journal-title":"Curr Pediatr Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines13101003","article-title":"Understanding vaccine hesitancy: insights and improvement strategies drawn from a multi-study review","volume":"25","author":"Brumbaugh","year":"2025","journal-title":"Vaccines."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1516126","DOI":"10.3389\/fphar.2025.1516126","article-title":"A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX","volume":"16","author":"Ludwig","year":"2025","journal-title":"Front Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"100175","DOI":"10.1016\/j.glmedi.2024.100175","article-title":"Pharmacovigilance. cosmetovigilance, hemovigilance, and materiovigilance in healthcare domains","volume":"5","author":"Yadav S","year":"2025","journal-title":"J Med Surg Public Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1630442","DOI":"10.3389\/fimmu.2025.1630442","article-title":"Impact of vaccination strategy adjustments on antibody levels against measles, rubella, mumps, and varicella in China: a single-center serological survey","volume":"16","author":"Geng","year":"2025","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2024075","DOI":"10.4178\/epih.e2024075","article-title":"Epidemic characteristics of measles and efforts to control measles infections in Zhejiang Province, China","volume":"46","author":"Yan","year":"2024","journal-title":"Epidemiol Health."},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines13010057","article-title":"Surveillance of adverse events following varicella vaccine immunization in Zhejiang Province, China, from 2020 to 2022","volume":"10","author":"Liang","year":"2025","journal-title":"Vaccines."},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines13040349","article-title":"Adverse events following haemophilus influenzae type b (HIB) monovalent vaccines in Zhejiang Province, China, from 2017 to 2023","volume":"25","author":"Pan","year":"2025","journal-title":"Vaccines."},{"key":"B23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijid.2020.07.019","article-title":"Safety of pentavalent DTaP-IPV\/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017","volume":"99","author":"Li","year":"2020","journal-title":"Int J Infect Dis Oct."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1186\/s12889-025-22615-5","article-title":"Surveillance of psychogenic adverse events following immunization in Zhejiang, China, 2020-2023","volume":"25","author":"Pan","year":"2025","journal-title":"BMC Public Health."},{"key":"B25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(25)01912-9","article-title":"Profiling vaccine attitudes and subsequent uptake in 11 million people in England: a nationwide cohort study","volume":"407","author":"Whitaker","year":"2026","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41541-024-00951-8","article-title":"COVID-19 vaccine refusal is driven by deliberate ignorance and cognitive distortions","volume":"9","author":"Fulawka","year":"2024","journal-title":"NPJ Vaccines."},{"key":"B27","first-page":"202","article-title":"Surveillance of adverse events following immunization with measlescontaining vaccines in Jinshan district of Shanghai, 2011-2020","volume":"34","author":"Zhou","year":"2023","journal-title":"Modern Dis Control Prevent"},{"key":"B28","first-page":"820","article-title":"Safety analysis of children of different ages vaccinated with measles, mumps and rubella combined attenuated live vaccine\/measles and rubella combined attenuated live vaccine in Jilin Province from 2015 to 2022","volume":"36","author":"Cao FF","year":"2023","journal-title":"Chin J Biologicals"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/vaccines13040417","article-title":"Safety analysis of simultaneous vaccination of japanese encephalitis attenuated live vaccine and measles, mumps, and rubella combined attenuated live vaccine from 2020 to 2023 in Guangzhou, China","volume":"16","author":"Liu","year":"2025","journal-title":"Vaccines."},{"key":"B30","first-page":"121","article-title":"Surveillance of adverse events following immunization in China, 2023","volume":"31","author":"Zhang","year":"2025","journal-title":"Chin J of Vaccines Immunization"},{"key":"B31","first-page":"470","article-title":"Surveillance of adverse events following immunization in China, 2021-2022","volume":"30","author":"Zhang","year":"2024","journal-title":"Chin J of Vaccines Immunization"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.vaccine.2018.02.012","article-title":"Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015","volume":"36","author":"Lei J","year":"2018","journal-title":"Vaccine."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e004898","DOI":"10.1136\/bmjgh-2020-004898","article-title":"Vaccine safety issues at the turn of the 21st century","volume":"6","author":"Conklin","year":"2021","journal-title":"BMJ Glob Health"},{"key":"B34","article-title":"Analysis on adverse events following immunization surveillance of measles attenuated livevaccine in China, 2005-2009","author":"Wu","year":"2010","journal-title":"Chin J of Vaccines Immunization"},{"key":"B35","first-page":"118","article-title":"Literature review of adverse events following immunization of measles attenuated live vaccine, 2000-2010","volume":"17","author":"WU","year":"2011","journal-title":"Chin J of Vaccines Immunization"},{"key":"B36","article-title":"Surveillance of adverse events following immunization with measles and rubella containing combination vaccines in Henanprovince, 2016-2018","author":"Wang","year":"2020","journal-title":"Chin J of Vaccines Immunization"},{"key":"B37","article-title":"Analysis of adverse events following immunization surveillance in Beichen District, Tianjin, 2013-2016","author":"Gao","year":"2020","journal-title":"Henan JPrev Med"},{"key":"B38","article-title":"The study on factors of adverse reactions of child vaccinationand nursing research","author":"Zhu","year":"2019","journal-title":"J Clin Nurs Pract"},{"key":"B39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jpids\/piz010","article-title":"Immunogenicity and safety of a measles-mumps-rubella vaccine administered as a first dose to children aged 12 to 15 months: a phase iii, randomized, noninferiority, lot-to-lot consistency study","volume":"9","author":"Klein","year":"2020","journal-title":"J Pediatric Infect Dis Soc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers17142410","article-title":"Novel therapeutics and the path toward effective immunotherapy in malignant peripheral nerve sheath tumors","volume":"21","author":"Lingo","year":"2025","journal-title":"Cancers."},{"key":"B41","unstructured":"Vaccine Reaction Rates Information Sheets on Measles, Mumps and Rubella Vaccines [Online]\n          \n          2014"},{"key":"B42","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/22221751.2021.1891002","article-title":"Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response","volume":"10","author":"Zhuang","year":"2021","journal-title":"Emerg Microbes Infect."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2592425","DOI":"10.1080\/21645515.2025.2592425","article-title":"Safety of co-administration of injectable vaccines in individuals under 18 years of age: a systematic literature review","volume":"21","author":"Boccalini","year":"2025","journal-title":"Hum Vaccin Immunother."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1846354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:56:25Z","timestamp":1781675785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1846354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":43,"alternative-id":["10.3389\/fpubh.2026.1846354"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1846354","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1846354"}}